blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3590944

EP3590944 - AZETIDINE DERIVATIVE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.07.2023
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  12.08.2022
FormerGrant of patent is intended
Status updated on  05.04.2022
FormerRequest for examination was made
Status updated on  06.12.2019
FormerThe international publication has been made
Status updated on  11.09.2018
Most recent event   Tooltip16.02.2024Lapse of the patent in a contracting state
New state(s): BE		published on 20.03.2024  [2024/12]
Applicant(s)For all designated states
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
No. 369 Yuzhou South Road
Lianyungang, Jiangsu 222062 / CN
[2020/02]
Inventor(s)01 / XIONG, Jian
Room 218
No.9 Gaoxin Road
Gaoxin Development District
Nanjing Jiangsu 210032 / CN
02 / XIE, Cheng
Room 218
No.9 Gaoxin Road
Gaoxin Development District
Nanjing Jiangsu 210032 / CN
03 / CHEN, Kevin X
Room 218
No.9 Gaoxin Road
Gaoxin Development District
Nanjing Jiangsu 210032 / CN
04 / XU, Xiongbin
Room 218
No.9 Gaoxin Road
Gaoxin Development District
Nanjing Jiangsu 210032 / CN
05 / ZHANG, Xuejin
Room 218
No.9 Gaoxin Road
Gaoxin Development District
Nanjing Jiangsu 210032 / CN
06 / GONG, Zhen
Room 218
No.9 Gaoxin Road
Gaoxin Development District
Nanjing Jiangsu 210032 / CN
07 / LI, Jian
Room 218
No.9 Gaoxin Road
Gaoxin Development District
Nanjing Jiangsu 210032 / CN
08 / CHEN, Shuhui
Room 218
No.9 Gaoxin Road
Gaoxin Development District
Nanjing Jiangsu 210032 / CN
09 / ZHANG, Aiming
No.369 Yuzhou South Rd.
Lianyungang Jiangsu 222062 / CN
10 / JIANG, Zhulian
No.369 Yuzhou South Rd.
Lianyungang Jiangsu 222062 / CN
11 / ZHANG, Xiquan
No.369 Yuzhou South Rd.
Lianyungang Jiangsu 222062 / CN
12 / TIAN, Xin
No.369 Yuzhou South Rd.
Lianyungang Jiangsu 222062 / CN
 [2020/02]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstraße 4
80802 München / DE
[2020/02]
Application number, filing date18760796.528.02.2018
[2020/02]
WO2018CN77583
Priority number, dateCN20171011235028.02.2017         Original published format: CN201710112350
CN20171080588308.09.2017         Original published format: CN201710805883
[2020/02]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018157820
Date:07.09.2018
Language:ZH
[2018/36]
Type: A1 Application with search report 
No.:EP3590944
Date:08.01.2020
Language:EN
[2020/02]
Type: B1 Patent specification 
No.:EP3590944
Date:14.09.2022
Language:EN
[2022/37]
Search report(s)International search report - published on:CN07.09.2018
(Supplementary) European search report - dispatched on:EP11.11.2020
ClassificationIPC:C07F5/02, A61K31/69, A61P35/00
[2020/02]
CPC:
A61P35/00 (EP,CN,IL,KR,US); C07F5/025 (EP,CN,IL,KR,US); A61K31/69 (IL,KR);
C07F5/02 (IL,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/02]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:AZETIDINDERIVAT[2020/02]
English:AZETIDINE DERIVATIVE[2020/02]
French:DÉRIVÉ D'AZÉTIDINE[2020/02]
Entry into regional phase30.09.2019Translation filed 
30.09.2019National basic fee paid 
30.09.2019Search fee paid 
30.09.2019Designation fee(s) paid 
30.09.2019Examination fee paid 
Examination procedure30.09.2019Amendment by applicant (claims and/or description)
30.09.2019Examination requested  [2020/02]
06.04.2022Communication of intention to grant the patent
08.08.2022Fee for grant paid
08.08.2022Fee for publishing/printing paid
08.08.2022Receipt of the translation of the claim(s)
Opposition(s)15.06.2023No opposition filed within time limit [2023/34]
Fees paidRenewal fee
13.02.2020Renewal fee patent year 03
12.02.2021Renewal fee patent year 04
28.01.2022Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
MC14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
BE28.02.2023
IE28.02.2023
LU28.02.2023
[2024/12]
Former [2024/08]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
MC14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
IE28.02.2023
LU28.02.2023
Former [2023/49]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
MC14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
LU28.02.2023
Former [2023/44]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
MC14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/37]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/34]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/30]AL14.09.2022
AT14.09.2022
CZ14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/29]AL14.09.2022
AT14.09.2022
CZ14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/26]AT14.09.2022
CZ14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/23]AT14.09.2022
CZ14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
PT16.01.2023
Former [2023/22]AT14.09.2022
CZ14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
PT16.01.2023
Former [2023/20]FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RS14.09.2022
SE14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
Former [2023/10]FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RS14.09.2022
SE14.09.2022
NO14.12.2022
GR15.12.2022
Former [2023/09]FI14.09.2022
LT14.09.2022
LV14.09.2022
RS14.09.2022
SE14.09.2022
NO14.12.2022
Former [2023/08]FI14.09.2022
LT14.09.2022
RS14.09.2022
SE14.09.2022
NO14.12.2022
Documents cited:Search[A]WO2006086600  (CEPHALON INC [US], et al) [A] 1-15 * page 112 - page 124; claims 1,17,18,22 *;
 [T]CN110790780  (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD) [T] 1-15* paragraphs [0045] , [0100] *;
 [A]  - BRUCE D. DORSEY ET AL, "Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer", JOURNAL OF MEDICINAL CHEMISTRY, (20080201), vol. 51, no. 4, doi:10.1021/jm7010589, ISSN 0022-2623, pages 1068 - 1072, XP055058105 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1021/jm7010589
International search[A]WO2006086600  (CEPHALON INC [US], et al) [A] 1-18, 20, 21;
 [A]CN105732683  (UNIV NANJING FORESTRY) [A] 1-18, 20, 21;
 [A]  - DOU, Q. PING, "Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System", Current Cancer Drug Targets, (20141231), vol. 14, no. 6, pages 517 - 36, XP055605937 [A] 1-18, 20, 21 * , *

DOI:   http://dx.doi.org/10.2174/1568009614666140804154511
 [A]  - RUGGERI B., "The development and pharmacology of proteasome inhibitors for the management and treatment of cancer", Advances in Pharmacology, San Diego , CA , United States, (20091231), vol. 57, doi:10.1016/S1054-3589(08)57003-7, pages 91 - 135, XP009516635 [A] 1-18, 20, 21

DOI:   http://dx.doi.org/10.1016/S1054-3589(08)57003-7
by applicant   - BERGE et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.